索拉非尼联合放疗治疗肝癌的临床有效性研究  

Clinical effectiveness of sorafenib combined with radiotherapy for hepatocellular carcinoma

作　　者：徐晓东[1] 燕丽萍[1] 张云峰[1] XU Xiao-dong;YAN Li-ping;ZHANG Yun-feng(Pingdu People's Hospital,Qingdao 266700,China)

机构地区：[1]平度市人民医院,266700

出　　处：《中国实用医药》2023年第9期107-109,共3页China Practical Medicine

摘　　要：目的探究肝癌患者应用索拉非尼联合放射治疗(放疗)的临床治疗效果。方法76例肝癌患者,利用随机盲选法分为试验组与参照组,各38例。参照组给予单纯放疗治疗,试验组在对照组基础上联合索拉非尼治疗。比较两组治疗前后的血小板衍生生长因子(PDGF)及血管内皮生长因子(VEGF)水平,1年疾病控制率(DCR)、1年生存率,不良反应发生情况。结果治疗后,试验组PDGF(3.97±1.08)ng/ml、VEGF(62.74±10.57)pg/ml低于参照组的(9.64±3.27)ng/ml、(129.51±12.32)pg/ml,差异有统计学意义(P<0.05)。试验组1年DCR为86.84%(33/38),1年生存率为84.21%(32/38);参照组1年DCR为65.79%(25/38),1年生存率为63.16%(24/38)。试验组1年DCR、1年生存率高于参照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论肝癌患者接受放疗联合索拉非尼治疗能有效改善PDGF及VEGR水平,有助于控制肿瘤转移,提高生存期,值得应用推广。Objective To investigate the clinical effect of sorafenib combined with radiotherapy for hepatocellular carcinoma.Methods A total of 76 patients with hepatocellular carcinoma were randomly divided into experimental group and reference group,with 38 cases in each group.The reference group was treated with radiotherapy alone,and the experimental group was treated with sorafenib on the basis of the control group.Both groups were compared in terms of levels of platelet-derived growth factor(PDGF)and vascular endothelial growth factor(VEGF)before and after treatment,1-year disease control rate(DCR),1-year survival rate,and occurrence of side reactions.Results After treatment,PDGF of(3.97±1.08)ng/ml and VEGF of(62.74±10.57)pg/ml in the experimental group were lower than those of(9.64±3.27)ng/ml and(129.51±12.32)pg/ml in the control group,and the differences were statistically significant(P<0.05).The experimental group had 1-year DCR of 86.84%(33/38)and the 1-year survival rate of 84.21%(32/38);the reference group had 1-year DCR of 65.79%(25/38)and the 1-year survival rate of 63.16%(24/38).The 1-year DCR and 1-year survival rate of the experimental group were higher than those of the reference group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of side reactions between the two groups(P>0.05).Conclusion In patients with hepatocellular carcinoma,radiotherapy combined with sorafenib can effectively improve the levels of PDGF and VEGR,help to control tumor metastasis and improve survival time,and is worthy of application and promotion.

关 键 词：索拉非尼 放射治疗 肝癌 临床效果 

分 类 号：R735.7[医药卫生—肿瘤]